A case of VEXAS syndrome associated with EBV-associated hemophagocytic lymphohistiocytosis
- 1 March 2022
- journal article
- research article
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 93, 102636
Abstract
No abstract availableKeywords
Funding Information
- CSL Behring
This publication has 24 references indexed in Scilit:
- The Ubiquitin–Proteasome System in Immune CellsBiomolecules, 2021
- Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory DiseaseNew England Journal of Medicine, 2020
- Nivolumab treatment of relapsed/refractory Epstein-Barr virus–associated hemophagocytic lymphohistiocytosis in adultsBlood, 2020
- Recommendations for the management of hemophagocytic lymphohistiocytosis in adultsBlood, 2019
- Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic DisordersJournal of Medicinal Chemistry, 2019
- Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infectionsBlood Advances, 2019
- Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancyHaematologica, 2018
- Ruxolitinib‐associated infections: A systematic review and meta‐analysisAmerican Journal of Hematology, 2017
- Adult haemophagocytic syndromeThe Lancet, 2014
- Treatment of Epstein Barr virus‐induced haemophagocytic lymphohistiocytosis with rituximab‐containing chemo‐immunotherapeutic regimensBritish Journal of Haematology, 2013